奥莫尔蒂尼布加贝瓦西祖马布治疗未经治疗的晚期NSCLC,具有EGFR敏感突变
Lingping Kong1, Lina Peng1, Xue Yang1
1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Frontiers in oncology
|June 19, 2025
概括
奥莫尔蒂尼布加贝瓦西祖马布在治疗晚期EGFR突变NSCLC方面显示出有前途的疗效. 这种组合疗法实现了12个月的PFS率为81%,并且耐受性良好.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 奥莫尔蒂尼布是一种第三代EGFR-TKI,用于EGFR突变的NSCLC.
- 关于EGFR-TKIs和贝瓦齐祖马布的组合在晚期NSCLC中进行辩论.
研究的目的:
- 评估aumolertinib和bevacizumab在未经治疗的EGFR突变NSCLC患者中的疗效和安全性.
主要方法:
- 第二阶段单臂前性临床试验.
- 21名患有晚期EGFRm NSCLC的患者接受了auomolertinib和bevacizumab.
- 主要终点:12个月无进展生存率 (PFS%).
主要成果:
- 12个月的PFS率为81% (95% CI:64.1-97.9%). 在12个月的PFS率为81% (95% CI:64.1-97.9%).
- 中位数PFS为26个月 (95% CI:16.5-35.5);目标响应率 (ORR) 为85.7%.
- 在中枢神经系统转移 (92.9%) 和TP53共突变 (86.6%) 亚组中观察到高ORR. 3级不良事件发生在19.2%的患者中.
结论:
- 奥莫尔蒂尼布加贝瓦西祖马布组合在晚期EGFRm NSCLC中达到其主要终点.
- 这种组合证明了延长PFS,并且是安全和耐受的.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.3K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
